- 1 Efficacy and safety of endocrine therapy after mastectomy in patients with
- 2 hormone receptor positive breast ductal carcinoma in situ: retrospective cohort
- 3 study

8

- **Authors:** Nan Niu^{1,2,3†}, Yinan Zhang^{1,2,3†}, Yang Bai^{4†}, Xin Wang⁵, Shunchao Yan¹, Dong Song⁶, Hong
- 6 Xu⁷, Tong Liu⁸, Bin Hua⁹, Yingchao Zhang¹⁰, Jinchi Liu^{1,2,3}, Xinbo Qiao^{1,2,3}, Jiaxiang Liu⁵, Xinyu
- 7 Zheng^{11*}, Hongyi Cao^{12*}, Caigang Liu^{1,2,3*}

9 Author Affiliations:

- 10 1. Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China;
- 11 2. Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of China Medical
- 12 University, Shenyang, China;
- 13 3. Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province,
- 14 Shenyang, China;
- 15 4. Department of Nursing, Shengjing Hospital of China Medical University, Shenyang 110004,
- 16 China;
- 17 5. Department of Breast Surgery, National Cancer Center/National Clinical Research Center for
- 18 Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical
- 19 College, Beijing, China;
- 20 6. Department of Breast Surgery, the First Hospital of Jilin University, Changchun, China;
- 21 7. Department of Breast Surgery, Liaoning Cancer Hospital and Institute, Cancer Hospital of China
- 22 Medical University, Shenyang, China;
- 23 8. Department of Breast Surgery, Cancer Hospital of Harbin Medical University, Harbin, China;
- 24 9. Department of General Surgery, Beijing Hospital, National Center of Gerontology, Institute of
- 25 Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China;
- 26 10. Department of Breast Surgery, the Second Hospital of Jilin University, Changchun, China;
- 27 11. Department of Breast Surgery, the First Affiliated Hospital of China Medical University,
- Shenyang, China;

29 12. Department of Pathology, the First Affiliated Hospital of China Medical University and College of 30 Basic Medical Sciences, Shenyang, China; 31 32 * Correspondence: 33 Corresponding Author 34 Caigang Liu, MD, PhD 35 Department of Oncology, Shengjing Hospital of China Medical University, Shenyang 110004, China 36 Tel.: 86-18940254967 37 E-mail: liucg@sj-hospital.org 38 ORCID: 0000-0003-2083-235X

39

41 *: Co-corresponding authors

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

Abstract Background: More than half of Chinese patients with hormone receptor positive (HR+) ductal carcinoma in situ (DCIS) are treated with mastectomy, and usually followed by endocrine therapy (ET). Given that long-term ET can cause severe adverse effects it is important to determine the beneficial effect and safety of adjuvant ET after mastectomy on the disease-free survival (DFS) and adverse events in patients with HR+ DCIS. Methods: To explore beneficial effect and safety of ET after mastectomy in patients with HR+ DCIS, we performed a multicenter, population-based study. This retrospective study analyzed the DFS and adverse events in 1037 HR+ DCIS Chinese patients with or without post-mastectomy ET from eight Breast Centers between 2006-2016. The median follow-up time was 86 months. **Results:** There were 791 DCIS patients receiving ET (ET group). Those patients were followed-up for a median of 86 months (range, 60-177 months). There were 23 cases with tumor recurrence or distant metastasis. There were similar 5-year DFS rates and DFS between the ET and non-ET groups, even for those with high risk factors. Conversely, 37.04% of patients suffered from adverse events after ET, which were significantly higher than those in the non-ET group. Conclusion: ET after mastectomy did not benefit patients with HR+ DCIS for their DFS, rather increased adverse events in those patients. Therefore, ET after mastectomy may not be recommended for patients with HR+ DCIS, even for those with high-risk factors, such as multifocal, microinvasive and higher T stage. Funding: This study was supported by grants from Outstanding Scientific Fund of Shengjing Hospital (201803) and Outstanding Young Scholars of Liaoning Province (2019-YQ-10).

Introduction:

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

Breast cancer screening in adult women has improved its early detection, increasing incidence of ductal carcinoma in situ (DCIS), which currently accounts for >20% of all new breast cancers in USA(Siegel, Miller, Fuchs, & Jemal, 2021). Breast-conserving surgery (BCS) plus radiotherapy (RT) has been widely used for the control of invasive cancer recurrence(Shah et al., 2016). Recent studies have shown that there is an increase in the percentages of DCIS patients for unilateral and bilateral mastectomy in USA, particularly for young patients (Byun, Wu, Nagar, & Gerber, 2021). There are approximate 30% of DCIS patients receiving mastectomy and potential breast reconstruction, especially for those with widespread, multicentric DCIS in USA(Warnberg et al., 2014; Worni et al., 2015). However, there are near 60% of DCIS patients receiving mastectomy in China, particularly in the economic underdeveloped regions, because they have fear of cancer recurrence (FCR) and subsequent treatment costs. Endocrine therapy (ET) with tamoxifen or aromatase inhibitor (AI) has been recommended for hormone receptor positive (HR+) breast cancer patients after BCS plus RT to reduce the risk of contralateral breast cancer (CBC) and ipsilateral breast tumor recurrence (IBTR) by National Comprehensive Cancer Network (NCCN)(Allred et al., 2012; Forbes et al., 2016; Ganz et al., 2016). It is notable that ET after bilateral mastectomy is not recommended for HR+ DCIS patients, who have a minimal risk for disease recurrence. However, ET still is being used for some HR+ DCIS patients post unilateral mastectomy in Western countries because ET has been thought to reduce the risk of contralateral recurrence of invasive and pure DCIS(Byun et al., 2021). In China, ET has been widely used for HR+ DCIS patients after mastectomy because of FCR although no specific recommendation of ET for them(Mao et al., 2021). Moreover, long-term ET can cause adverse effects, particularly for

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

post-menopausal women. However, there is no report whether ET after unilateral mastectomy can benefit Chinese HR+ DCIS patients for reducing contralateral recurrence of breast cancer and prolonging disease-free survival (DFS) as well as its safety. Accordingly, this retrospective cohort study evaluated the efficacy and safety of ET after mastectomy in the DFS and adverse events of 1037 HR+ DCIS patients. Methods **Subjects** This study was approved by the Institutional Review Board of Shengjing Hospital (approval number: 2020PS014K). This retrospective cohort study reviewed and analyzed the DFS and adverse events in 1037 HR+ DCIS patients with, or without, ET after mastectomy from December 2006 to August 2016 (Figure 1). The inclusion criteria included 1) Age > 18; 2) pathological diagnosis of HR+ DCIS regardless of Her-2 status; 3) receiving mastectomy regardless of treatment with ET; 4) complete medical records with regular post-operative follow-up at least for 5 years. Data collection and statistical analysis The demographic and clinical data, including age, menopausal status, diagnosis, tumor pathological index, adjuvant treatments (drugs, duration), the ET-related adverse effects, tumor recurrence and survival status were collected. The tumor recurrence was defined as pathologically confirmed breast cancer (DCIS, invasive breast cancer) or metastatic cancers. The DFS was calculated from the diagnosis to the tumor recurrence, or the last follow-up. All patients were stratified, based on ET, and their demographic and clinical data were analyzed by Chi-square, Fisher's exact and Wilcoxon rank sum tests where applicable. Their DFS was estimated using Kaplan-Meier method and analyzed by the Log-rank test. The potential risk of individual factors for the tumor recurrence was analyze by hazard ratios (HR) and 95% confidence intervals (CI). All statistical analyses were performed by SPSS 24.0 software (SPSS, Chicago, USA). Statistical significance was defined when a two-tailed P-value of <0.05.

Results

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

ET after mastectomy does not significantly alter the DFS of HR+ DCIS patients.

A total of 1007 HR+ DCIS patients with mastectomy were selected and their demographic and clinical data, are shown in *Table 1*. According to ET treatment, those patients were stratified in the ET (n=791) and non-ET (n=216) groups. There was no significant difference in any of the demographic and clinical measures tested between these two groups. There were 23 cases (19 vs. 4 between the ET and non-ET groups) with tumor recurrence, leading to 2.40% vs. 1.85% (p > 0.05, determined by Fisher exact test) of tumor recurrence rate in the ET and non-ET groups throughout the 12 years post-surgical observation (Table 2). There were 4 cases with invasive local recurrence, 3 with contralateral breast cancer, 12 with distant metastasis in the ET group while 4 cases with distant metastases in the non-ET group. Stratification analyses indicated the tumor recurrence rate was not significantly associated with these measures, including high risk factors in this population (P>0.05 for all, *Table 3*). There was no significantly difference in the percentages of patients with a 5-year DFS rate of 98.36% vs. 99.07% between the ET and non-ET groups (P = 0.44, Figure 2A). Further analysis revealed that there was also no significant difference in the percentages of patients with DFS between these subgroups (P > 0.05 for all, Figure 2B-F), suggesting that the age, larger tumor size, positive microinvasive, higher tumor grade and Ki67 levels were not associated with increased risk of worse

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

DFS in this population. Hence, ET after mastectomy did not significantly reduce the tumor recurrence rate and prolong the DFS in HR+ DCIS patient. The ET-related adverse effects ET can cause musculoskeletal dysfunction, vasomotor symptoms, gynecological events, cardiovascular events and abnormal liver-function in women, particularly in postmenopausal women. There were 551 patients receiving tamoxifen, 223 with AI and others beginning with tamoxifen and later switching to AI. Analysis of adverse events in both groups revealed that 37.04% of patients in the ET group developed at least one adverse event, including bone fracture or endometrial cancer (n=4 each), while 15.28% of cases with these events in the non-ET group. There were 14.54% of patients with musculoskeletal dysfunctions, such as arthralgia, joint stiffness, osteoporosis or myalgia in the ET group and the percentages of some adverse events tested in the ET group were significantly higher than that in the non-ET group in this population (Figure 3). Adverse events between TAM and AI in the ET group are shown in Table 4. Therefore, ET after mastectomy was associated with increased risk for development of different types of adverse effects in patients with HR+ DCIS. **Discussion** Therapeutic strategies for HR+ DCIS, including mastectomy or BCS plus RT, have achieved a similarly high survival rate in patients (Mannu et al., 2020; Narod, Iqbal, Giannakeas, Sopik, & Sun, 2015). Although ET after BCS plus RT is recommended for patients with HR+ DCIS, and benefits for those with positive surgical margin(Allred et al., 2012; Forbes et al., 2016; Ganz et al., 2016; Wapnir et al., 2011), many HR+ DCIS Asian patients chose mastectomy and received ET(Mao et al., 2021; Worni et al., 2015). In the present study, 78.55 % of HR+ DCIS patients were treated with post-mastectomy ET. More importantly, we found that there was no significant difference in 5-year DFS rate and tumor recurrence rate in HR+ DCIS patients regardless of ET, even in those with high risk factors for tumor recurrence. To the best of our knowledge, this was the first report on the efficacy of ET after mastectomy in the DFS of Chinese HR+DCIS patients and these novel findings clearly indicated that ET after mastectomy did not prolong the DFS of HR+ DCIS patients. Long-term ET can cause multiple adverse effects, affecting the life-quality of patients. Indeed, 37.04% of patients suffered from adverse events following ET. Quantitative analysis revealed that the percentages of patients with musculoskeletal dysfunction, gynaecological events and abnormal liver-function, but not vasomotor symptoms and cardiovascular events in the ET group were significantly higher than that in the non-ET group of patients. The increased percentages of patients with these clinical symptoms demonstrated that long-term ET caused multiple adverse effects in HR+ DCIS patients after mastectomy. Given that the majority of HR+ DCIS patients chose mastectomy with a long DFS and ET after mastectomy did not prolong their DFS, rather significantly increased ET-related adverse effects in those patients, our findings suggest that ET may be decreased for its dose and duration or completely avoided for HR+ DCIS patients following mastectomy to improve their life-quality. Several limitations of our study include its retrospective nature and the length of follow-up. To fully evaluate the differences in treatment, longer follow-up and randomized trials are necessary.

Conclusions

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

ET after mastectomy did not prolong the DFS of HR+ DCIS patients, rather increased adverse effects.

Our findings suggest not providing ET for HR+ DCIS patients after mastectomy.

Competing interests

175 Caigang Liu: Senior editor, *eLife*. The other authors declare that no competing interests exist.

176 Funding

Funder	Grant reference number	Author	
Outstanding Young Scholars of	2019-YQ-10	Caigang Liu	
Liaoning Province			
Outstanding Scientific Fund of	201803	Caigang Liu	
Shengjing Hospital			
The funders had no role in study design, data collection and interpretation, or the decision to submit			
the work for publication.			

Author contributions

Nan Niu, Data curation, Formal analysis, Writing – original draft preparation, Writing – review & editing; Yinan Zhang, Investigation, Data curation, Formal analysis; Yang Bai, Investigation, Data curation; Xin Wang, Investigation, Data curation; Shunchao Yan, Writing – original draft preparation; Dong Song, Investigation, Data curation; Hong Xu, Investigation, Data curation; Tong Liu, Investigation, Data curation; Bin Hua, Investigation, Data curation; Yingchao Zhang, Investigation, Data curation; Jinchi Liu, Methodology, Formal analysis; Xinbo Qiao, Methodology, Formal analysis; Jiaxiang Liu, Investigation, Data curation; Xinyu Zheng, Conceptualization, Supervision, Project administration; Hongyi Cao, Investigation, Data curation, Formal analysis; Caigang Liu, Conceptualization, Funding acquisition, Project administration, Writing - review and editing.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files.

Author ORCIDs

190 Nan Niu https://orcid.org/0000-0002-8206-941X

191

Caigang Liu http://orcid.org/0000-0003-2083-235X

192 References 193 194 Allred, D. C., Anderson, S. J., Paik, S., Wickerham, D. L., Nagtegaal, I. D., Swain, S. M., . . . 195 Wolmark, N. (2012). Adjuvant tamoxifen reduces subsequent breast cancer in women 196 with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP 197 protocol B-24. J Clin Oncol, 30(12), 1268-1273. doi:10.1200/JCO.2010.34.0141 198 Byun, D., Wu, S., Nagar, H., & Gerber, N. (2021). Ductal Carcinoma in Situ in Young Women: 199 Increasing Rates of Mastectomy and Variability in Endocrine Therapy Use. Annals of 200 surgical oncology, 28(11), 6083-6096. doi:10.1245/s10434-021-09972-2 201 Forbes, J. F., Sestak, I., Howell, A., Bonanni, B., Bundred, N., Levy, C., . . . Cuzick, J. (2016). 202 Anastrozole versus tamoxifen for the prevention of locoregional and contralateral 203 breast cancer in postmenopausal women with locally excised ductal carcinoma in situ 204 (IBIS-II DCIS): a double-blind, randomised controlled trial. The Lancet, 387(10021), 205 866-873. doi:10.1016/s0140-6736(15)01129-0 206 Ganz, P. A., Cecchini, R. S., Julian, T. B., Margolese, R. G., Costantino, J. P., Vallow, L. A., . . . 207 Wolmark, N. (2016). Patient-reported outcomes with anastrozole versus tamoxifen for 208 postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus 209 radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. The 210 Lancet, 387(10021), 857-865. doi:10.1016/s0140-6736(15)01169-1 211 Mannu, G. S., Wang, Z., Broggio, J., Charman, J., Cheung, S., Kearins, O., . . . Darby, S. C. 212 (2020). Invasive breast cancer and breast cancer mortality after ductal carcinoma in 213 situ in women attending for breast screening in England, 1988-2014: population based

214 observational cohort study. BMJ, 369, m1570. doi:10.1136/bmj.m1570 215 Mao, G., Shi, X., Wang, X., Zhang, X., Chen, X., Ma, J., . . . Guo, X. (2021). Clinicopathological 216 Characteristics of Breast Ductal Carcinoma In Situ: An Analysis of Chinese Population 217 of 617 Patients. Journal of oncology, 2021, 8854418. doi:10.1155/2021/8854418 218 Narod, S. A., Igbal, J., Giannakeas, V., Sopik, V., & Sun, P. (2015). Breast Cancer Mortality 219 After a Diagnosis of Ductal Carcinoma In Situ. JAMA Oncology, 220 doi:10.1001/jamaoncol.2015.2510 221 Shah, C., Wobb, J., Manyam, B., Kundu, N., Arthur, D., Wazer, D., . . . Vicini, F. (2016). 222 Management of Ductal Carcinoma In Situ of the Breast: A Review. JAMA Oncol, 2(8), 223 1083-1088. doi:10.1001/jamaoncol.2016.0525 224 Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2021). Cancer Statistics, 2021. CA 225 Cancer J Clin, 71(1), 7-33. doi:10.3322/caac.21654 226 Wapnir, I. L., Dignam, J. J., Fisher, B., Mamounas, E. P., Anderson, S. J., Julian, T. B., . . . 227 Wolmark, N. (2011). Long-term outcomes of invasive ipsilateral breast tumor 228 recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for 229 DCIS. J Natl Cancer Inst, 103(6), 478-488. doi:10.1093/jnci/djr027 230 Warnberg, F., Garmo, H., Emdin, S., Hedberg, V., Adwall, L., Sandelin, K., . . . Holmberg, L. 231 (2014). Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in 232 situ: 20 years follow-up in the randomized SweDCIS Trial. J Clin Oncol, 32(32), 233 3613-3618. doi:10.1200/JCO.2014.56.2595 234 Worni, M., Akushevich, I., Greenup, R., Sarma, D., Ryser, M. D., Myers, E. R., & Hwang, E. S. 235 (2015). Trends in Treatment Patterns and Outcomes for Ductal Carcinoma In Situ. J 236 Natl Cancer Inst, 107(12), djv263. doi:10.1093/jnci/djv263

237

238 Figure legends: 239 Figure 1. Flow chart of the study. 240 Figure 2. The disease-free survival of HR+ DCIS patients with or without post mastectomy ET. 241 Kaplan-Meier analysis indicated that there was no significant difference in the DFS of HR+ DCIS patients between 242 those with and without post-mastectomy ET. (A) There was no significant difference in the DFS of HR+ DCIS 243 patients with age < 50, (B) a larger tumor, (C) positive microinvasive, (D) higher tumor grade, (E) higher Ki67 244 level, (F) between those with and without post-mastectomy ET. HR, hormone receptor; DCIS, ductal carcinoma in 245 situ; ET, endocrine therapy; DFS, disease-free survival. 246 Figure 3. The frequency of patients with adverse effects between the ET and non-ET groups. 247 Data are expressed as % of cases with adverse events and real case numbers labeled and analyzed by Chi-squared 248 test. *P<0.05, **P<0.01, ***P<0.001. ET, endocrine therapy.

Table 1. The demographic and clinical characteristics of patients.

250

251

		0.134
448 (57%)	110 (51%)	
343 (43%)	106 (49%)	
		0.839
459 (58%)	127 (59%)	
332 (42%)	89 (41%)	
		0.322
128 (16%)	29 (13%)	
663 (84%)	187 (87%)	
		0.190
565 (71%)	164 (76%)	
226(29%)	52 (24%)	
		0.071
279 (35%)	62 (29%)	
512 (65%)	154 (71%)	
		0.310
64 (8%)	13 (6%)	
727 (92%)	203 (94%)	
	343 (43%) 459 (58%) 332 (42%) 128 (16%) 663 (84%) 565 (71%) 226(29%) 279 (35%) 512 (65%) 64 (8%)	343 (43%) 106 (49%) 459 (58%) 127 (59%) 332 (42%) 89 (41%) 128 (16%) 29 (13%) 663 (84%) 187 (87%) 565 (71%) 164 (76%) 226(29%) 52 (24%) 279 (35%) 62 (29%) 512 (65%) 154 (71%) 64 (8%) 13 (6%)

Notes: Data are n (%). ET, endocrine therapy.

Table 2. Tumor recurrence rates in patients with HR+ DCIS after mastectomy.

252

253

254

Tumor Recurrence	ET (<i>N</i> =19)	Non ET (<i>N</i> =4)
Invasive Local Recurrence	4 (21%)	0 (0%)
Contralateral Breast Cancer	3 (16%)	0 (0%)
Distant Metastasis		
Bone	6 (32%)	1 (25%)
Liver	2 (11%)	2 (50%)
Lung	1 (5%)	0 (0%)
Brain	1 (5%)	0 (0%)
Abdominal Cavity	1 (5%)	1 (25%)
Lymph nodes	1 (5%)	0 (0%)

Notes: Data are n (%). HR, hormone receptor; DCIS, ductal carcinoma in situ; ET, endocrine therapy.

Table 3. Stratification analysis of tumor recurrence rates in patients with HR+ DCIS after mastectomy.

Characteristic	ET (<i>N</i> =791)	Non ET (N=216)	HR (95% CI)	p-Value
Total	19 (791)	4 (216)	1.30 (0.48 to 3.52)	0.64
Age				
≤50	12 (448)	1 (110)	2.91 (0.74 to 11.47)	0.28
>50	7 (343)	3 (106)	0.75 (0.18 to 3.17)	0.67
Tumor size				
≤20mm	6 (459)	2 (127)	0.82 (0.15 to 4.44)	0.81
>20mm	13 (332)	2 (89)	1.75 (0.51 to 6.04)	0.45
Microinvasive				
Yes	8 (128)	0 (29)	3.48 (0.60 to 20.02)	0.16
No	11 (663)	4 (187)	0.76 (0.22 to 2.59)	0.64
Tumor grade				
1-11	10 (565)	0 (164)	3.64 (0.82 to 16.06)	0.09
Ш	9 (226)	4 (52)	0.51 (0.13 to 2.07)	0.26
Ki67				
≥15%	7 (279)	1 (62)	0.88 (0.09 to 8.29)	0.67
<15%	12 (512)	3 (154)	1.42 (0.46 to 4.38)	0.74
Multifocal				
Yes	3 (64)	0 (13)	3.34 (0.17 to 67.46)	0.43
No	16 (727)	4 (203)	1.11 (0.38 to 3.22)	0.85

Notes: HR, hormone receptor; DCIS, ductal carcinoma in situ; ET, endocrine therapy.

Table 4. Adverse events between TAM and AI in the ET group.

259

260

261

Adverse Events	TAM (<i>N</i> =551)	AI (N=223)
Total	212 (38%)	76 (34%)
Musculoskeletal Symptoms	61 (11%)	52 (23%)
Vasomotor Symptoms	42 (8%)	12 (5%)
Gynecological Events	113 (21%)	5 (2%)
Cardiovascular Events	26 (5%)	12 (5%)
Abnormal Liver-function	10 (2%)	4 (2%)

Notes: TAM, tamoxifen; AI, aromatase inhibitor; ET, endocrine therapy.





